NovaBay Pharmaceuticals Pivots to Stablecoins After $134M Investment; Stock Surges 19%

NovaBay Pharmaceuticals has announced a radical shift in its business strategy, officially rebranding as Stablecoin Development Corp. This transformation follows a significant capital injection of $134 million aimed at pivoting the company toward the Sky protocol and stablecoin development. Originally founded in 2000 as a biotechnology firm specializing in eyecare products, the company is now abandoning its medical roots to enter the digital asset sector. Investors reacted positively to the news, driving the company's stock price up by 19% immediately following the announcement. The move highlights a growing trend of traditional firms seeking new growth avenues within the decentralized finance ecosystem. While the immediate market reaction is bullish, analysts remain focused on the company's ability to successfully transition from pharmaceuticals to crypto infrastructure in the long term.

Sources:cointelegraph.comstocktitan.netainvest.comthestreet.comphemex.comcointelegraph.comgurufocus.combankless.comtradingview.comkavout.combenzinga.com